Known targets — ChEMBL curated mechanism
The experimentally established mechanism targets of Azelastine. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HRH1 known ✓ | P35367 | 17/20 | 1.00 |
| ▸ | ADRA1A | P35348 | 17/20 | 1.00 |
| ▸ | ADRA1B | P35368 | 17/20 | 1.00 |
| ▸ | HRH3 | Q9Y5N1 | 12/20 | 1.00 |
| ▸ | KCNH2 | Q12809 | 6/20 | 1.00 |
| ▸ | ADRA2A | P08913 | 2/20 | 1.00 |
| ▸ | CHRM1 | P11229 | 2/20 | 1.00 |
| ▸ | ADRA2B | P18089 | 2/20 | 1.00 |
| ▸ | HTR2A | P28223 | 2/20 | 1.00 |
| ▸ | DRD3 | P35462 | 2/20 | 1.00 |
| ▸ | ABCB1 | P08183 | 2/20 | 1.00 |
| ▸ | CHRM2 | P08172 | 1/20 | 1.00 |
| ▸ | ADRB1 | P08588 | 1/20 | 1.00 |
| ▸ | CYP2D6 | P10635 | 1/20 | 1.00 |
| ▸ | GABRA1 | P14867 | 1/20 | 1.00 |
| ▸ | ADRA2C | P18825 | 1/20 | 1.00 |
| ▸ | SLC6A2 | P23975 | 1/20 | 1.00 |
| ▸ | HTR2C | P28335 | 1/20 | 1.00 |
| ▸ | SLC6A4 | P31645 | 1/20 | 1.00 |
| ▸ | OPRM1 | P35372 | 1/20 | 1.00 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Azelastine SCHEMBL4240 | 1.00 | ADRA1A (1.00) | ADRA1AHRH1ADRA1BHRH3KCNH2 | |
| Azelastine SCHEMBL17223862 | 1.00 | ADRA1A (1.00) | ADRA1AHRH1ADRA1BHRH3KCNH2 | |
| Azelastine SCHEMBL30910968 | 1.00 | ADRA1A (1.00) | ADRA1AHRH1ADRA1BHRH3KCNH2 | |
| Azelastine SCHEMBL29370712 | 1.00 | ADRA1A (1.00) | ADRA1AHRH1ADRA1BHRH3KCNH2 | |
| Azelastine SCHEMBL4239 | 1.00 | ADRA1A (1.00) | ADRA1AHRH1ADRA1BHRH3KCNH2 | |
| Azelastine SCHEMBL4433245 | 1.00 | ADRA1A (1.00) | ADRA1AHRH1ADRA1BHRH3KCNH2 | |
| Azelastine SCHEMBL36770 | 0.99 | ADRA1A (1.00) | ADRA1AHRH1ADRA1BHRH3KCNH2 | |
| Azelastine SCHEMBL19458799 | 0.99 | ADRA1A (1.00) | ADRA1AHRH1ADRA1BHRH3KCNH2 | |
| Azelastine SCHEMBL4012083 | 0.99 | ADRA1A (0.98) | ADRA1AHRH1ADRA1BHRH3KCNH2 | |
| Azelastine SCHEMBL36771 | 0.99 | ADRA1A (1.00) | ADRA1AHRH1ADRA1BHRH3KCNH2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230142221-A1 | COMPOSITIONS AND METHODS FOR MODULATING ACE2 RECEPTOR | MUBARAK KAMAL KHAN (US) | 2023-05-11 | — | — | US | disclosed |
| US-20230142221-A1 | COMPOSITIONS AND METHODS FOR MODULATING ACE2 RECEPTOR | MUBARAK KAMAL KHAN (US) | 2023-05-11 | — | — | US | disclosed |
| US-20200206220-A1 | HETEROCYCLIC COMPOUNDS AS EPHA4 INHIBITORS | THE HONG KONG UNIVERSITY OF SCIENCE AND TECHNOLOGY (CN) | 2020-07-02 | — | — | US | disclosed |
| US-9359376-B2 | Substituted methylformyl reagents and method of using same to modify physicochemical and/or pharmacokinetic properties of compounds | SPHAERA PHARMA PTE. LTD (SG) | 2016-06-07 | — | — | US | disclosed |
| US-9359376-B2 | Substituted methylformyl reagents and method of using same to modify physicochemical and/or pharmacokinetic properties of compounds | SPHAERA PHARMA PTE. LTD (SG) | 2016-06-07 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230142221-A1 | COMPOSITIONS AND METHODS FOR MODULATING ACE2 RECEPTOR | ACE2, ACE, AGTR2 | HRH1 2618/4885ADRA1A 376/4885ADRA1B 480/4885 |
| US-20200206220-A1 | HETEROCYCLIC COMPOUNDS AS EPHA4 INHIBITORS | EPHA4, EPHA8, EPHA1 | HRH1 409/4885ADRA1A 3741/4885ADRA1B 3885/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.